脂肪酸代谢重编程在弥漫性大B细胞淋巴瘤中的研究进展

doi:10.16352/j.issn.1001-6325.2026.04.0582

基础医学与临床 ›› 2026, Vol. 46 ›› Issue (4): 582-586.doi: 10.16352/j.issn.1001-6325.2026.04.0582

脂肪酸代谢重编程在弥漫性大B细胞淋巴瘤中的研究进展

刘靖靖¹, 李燕^2*

1.新疆医科大学研究生院,新疆乌鲁木齐 830001;
2.新疆维吾尔自治区人民医院血液病科,新疆乌鲁木齐 830001

收稿日期:2025-07-19 修回日期:2025-11-27 发布日期:2026-03-24
通讯作者: ^*liyan232917@139.com
基金资助:
国家自然科学基金(82360040)

Research progress on fatty acid metabolism reprogramming in diffuse large B-cell lymphoma

LIU Jingjing¹, LI Yan^2*

1. Graduate School of Xinjiang Medical University, Urumqi 830001;
2. Department of Hematology, People′s Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China

Received:2025-07-19 Revised:2025-11-27 Published:2026-03-24
Contact: ^*liyan232917@139.com

摘要/Abstract

摘要： 弥漫性大B细胞淋巴瘤(DLBCL)是非霍奇金淋巴瘤(NHL)中最为常见的亚型,其发展机制与肿瘤微环境密切相关。脂肪酸代谢重编程是肿瘤代谢重编程的核心环节之一,在DLBCL的脂肪酸合成、摄取及β-氧化等过程中存在异常调控,不仅为肿瘤细胞快速增殖提供能量与结构物质,也会通过调控信号通路、表观遗传修饰等方式影响DLBCL的发生发展。本文梳理脂肪酸代谢酶、信号通路及微环境的作用,探索潜在诊断标志物或治疗靶点,旨在为完善DLBCL的分子机制及精准治疗提供新的思路。

关键词: 弥漫性大B细胞淋巴瘤, 脂肪酸代谢重编程, 肿瘤代谢, 肿瘤微环境, 治疗靶点

Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, and its progression is closely linked to the tumor microenvironment. Fatty acid metabolic reprogramming is one of the core aspects of tumor metabolic reprogramming. In DLBCL, abnormal regulation of fatty acid synthesis, uptake, and β-oxidation not only provides energy and structural materials for rapid tumor cell proliferation, but also influences disease initiation and progression by regulating signaling pathways and epigenetic modifications. This article reviews the roles of fatty acid metabolic enzymes, signaling pathways, and the microenvironment, and explores potential diagnostic biomarkers or therapeutic targets, aiming to provide new insights for elucidating molecular mechanisms underlying DLBCL development and advancing precise therapy.

Key words: diffuse large B-cell lymphoma, fatty acid metabolism reprogramming, tumor metabolism, tumor microenvironment, therapeutic targets

中图分类号:

R733.4

刘靖靖, 李燕. 脂肪酸代谢重编程在弥漫性大B细胞淋巴瘤中的研究进展[J]. 基础医学与临床, 2026, 46(4): 582-586.

LIU Jingjing, LI Yan. Research progress on fatty acid metabolism reprogramming in diffuse large B-cell lymphoma[J]. Basic & Clinical Medicine, 2026, 46(4): 582-586.

参考文献

[1] Cho Y,Lee J,Han B, et al. Tumor-infiltrating T lymphocytes evaluated using digital image analysis predict the prognosis of patients with diffuse large B-cell lymphoma[J]. J Pathol Transl Med,2024,58:12-21.
[2] Shi H, Pan Y, Xiang G, et al. A novel NET-related gene signature for predicting DLBCL prognosis[J].J Transl Med,2023,21:630.doi: 10.1186/s12967-023-04494-9.
[3] Zheng Y, Xu R, Chen X, et al. Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment[J]. Cell Death Dis, 2024,15:775.doi: 10.1186/s12967-023-04494-9.
[4] Elia I, Haigis MC. Metabolites and the tumour microenvironment:from cellular mechanisms to systemic metabolism[J].Nat Metab,2021,3:21-32.
[5] Kai Y, Xiaokun W, Chenghu S, et al. The role of lipid metabolic reprogramming in tumor microenvironment[J]. Theranostics, 2023,13:1774-1808.
[6] Dong C, Zhang Y, Zeng J, et al. FUT2 promotes colorectal cancer metastasis by reprogramming fatty acid metabolism via YAP/TAZ signaling and SREBP-1[J]. Commun Biol, 2024,7:1297.doi: 10.1038/s42003-024-06993-x.
[7] Lim SA, Su W, Chapman NM, et al. Lipid metabolism in T cell signaling and function[J]. Nat Chem Biol, 2022,18:470-481.
[8] Raychaudhuri D, Singh P, Chakraborty B, et al. Histone lactylation drives CD8⁺ T cell metabolism and function[J]. Nat Immunol, 2024,25:2140-2151.
[9] Li C, Wang F, Cui L, et al. Association between abnormal lipid metabolism and tumor[J]. Front Endocrinol (Lausanne), 2023,14:1134154.doi: 10.1038/s42003-024-06993-x.
[10] Li Y, Wang L, Wang J, et al.Relationship between adipocytes and hematological tumors in the bone marrow microenvironment: a literature review[J]. Transl Cancer Res, 2024,13:5691-5701.
[11] Pera B, Krumsiek J, Assouline E S, et al. Metabolo-mic profiling reveals cellular reprogramming of B-cell lymphoma by a lysine deacetylase inhibitor through the choline pathway[J]. EBioMedicine, 2018,28:80-89.
[12] Wang X, Liu H, Fei Y, et al. Metabolic pathway-based subtyping reveals distinct microenvironmental states associated with diffuse large B-cell lymphoma outcomes[J]. Hematol Oncol, 2024,42:e3279.doi: 10.1002/hon.3279.
[13] Zhong X,Zhang W,Zhang W, et al. FASN contributes to ADM resistance of diffuse large B-cell lymphoma by inhibiting ferroptosis via nf-κB/STAT3/GPX4 axis[J]. Cancer Biol Ther,2024,25:2403197.doi: 10.1080/15384047.2024.2403197.
[14] Kapadia B, Nanaji NM, Bhalla K, et al. Fatty acid synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL[J]. Nat Commun, 2018,9:829.doi: 10.1038/s41467-018-03028-y.
[15] Danilova OV, Dumont LJ, Levy NB, et al. FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma[J]. J Hematop, 2013,6:11-18.
[16] Meng Y, Guo D, Lin L, et al. Glycolytic enzyme PFKL governs lipolysis by promoting lipid droplet-mitochondria tethering to enhance β-oxidation and tumor cell prolifera-tion[J]. Nat Metab, 2024,6:1092-1107.
[17] Caro P, Kishan U A, Norberg E, et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma[J]. Cancer Cell, 2012,22:547-560.
[18] 张漪蓉, 魏玮庆, 马皎, 等. 靶向SOX9调控弥漫性大B细胞淋巴瘤代谢重编程的研究[J]. 上海交通大学学报(医学版),2023,43:1236-1244.
[19] Wang X, Liu H, Fei Y, et al. Metabolic pathway-based subtyping reveals distinct microenvironmental states associated with diffuse large B-cell lymphoma outcomes[J]. Hematol Oncol, 2024,42:e3279.doi: 10.1002/hon.3279.
[20] 崔建, 陈烨, 何丽, 等. 脂肪酸代谢相关基因ACSL1在急性髓系白血病中的作用及潜在价值[J]. 癌变·畸变·突变,2024,36:298-304.
[21] Nemec R,Crosbie SM,Abramson SJ, et al. Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP[J]. Leuk Lymphoma,2024,65:1-6.
[22] Liu MK, Cheng LL, Yi HM, et al. Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma[J]. Front Oncol, 2022,12:885011.doi: 10.3389/fonc.2022.885011.

脂肪酸代谢重编程在弥漫性大B细胞淋巴瘤中的研究进展

Research progress on fatty acid metabolism reprogramming in diffuse large B-cell lymphoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘睿琦, 张建民, 何维, 陈慧. FBXO2是Vδ1 γδ T细胞识别的肿瘤相关异位蛋白质配体[J]. 基础医学与临床, 2026, 46(7): 887-894.
[2]	王艳贺, 王恬, 杨清竹, 刘爱春. EXOSC5高表达抑制弥漫性大B细胞淋巴瘤细胞系SU-DHL-4和OCI-LY3铁死亡[J]. 基础医学与临床, 2026, 46(5): 621-628.
[3]	陈梦蕾, 崔云. Notch信号通路在支气管哮喘中的作用[J]. 基础医学与临床, 2026, 46(2): 293-297.
[4]	李彬凤, 吕发友, 易辉君, 吕侣. 环指蛋白家族在乳腺癌中作用机制的研究进展[J]. 基础医学与临床, 2026, 46(1): 124-128.
[5]	周慧聪, 邵亚娟. 老年肿瘤微环境对免疫检查点抑制剂治疗的影响[J]. 基础医学与临床, 2025, 45(9): 1139-1143.
[6]	龙丽娟, 宋松泽, 叶棋浓, 蔺静. LSD1调控肿瘤免疫机制的研究进展[J]. 基础医学与临床, 2025, 45(8): 1088-1092.
[7]	李云帆, 邹佳铭, 王钰铖, 鞠瑞, 郭磊. CTO抑制小鼠胶质瘤细胞原位生长并调节相关小胶质细胞代谢及炎性表型[J]. 基础医学与临床, 2025, 45(4): 478-485.
[8]	楼海均, 孟·孟根, 张振宇, 童卓云, 乌都木丽. 跨膜蛋白33在肿瘤发生发展中的作用[J]. 基础医学与临床, 2025, 45(2): 258-262.
[9]	张彦池, 施俊琦, 张一君, 段佳文, 刘进宇, 张丽燕, 梁晚平. 乳腺癌代谢机制与免疫微环境靶向的协同治疗进展[J]. 基础医学与临床, 2025, 45(12): 1662-1667.
[10]	刘保清, 黄容, 卢艳, 李凯, 张宁, 刘长征, 宋伟. 胃癌类器官在基础研究与临床应用中的进展[J]. 基础医学与临床, 2024, 44(9): 1219-1222.
[11]	李阳, 朱蕾. 真核延伸因子2激酶是治疗肿瘤的潜在新靶标[J]. 基础医学与临床, 2024, 44(7): 1039-1043.
[12]	李瑗春, 严学倩, 范丹, 及月茹, 肖方, 高静. AP2M1抑制弥漫性大B细胞淋巴瘤细胞增殖和侵袭[J]. 基础医学与临床, 2024, 44(3): 308-316.
[13]	刘柯, 戴梦华. 胰腺癌中谷氨酰胺代谢重构的研究进展[J]. 基础医学与临床, 2024, 44(11): 1613-1617.
[14]	张海灵, 杨玉, 周倩倩, 汪远金, 王婷. 微囊藻毒素-LR处理的中性粒细胞NETs促进结直肠癌细胞迁移[J]. 基础医学与临床, 2023, 43(6): 967-973.
[15]	李凯, 王亚南. 氢氧化钠增强雷帕霉素抑制Tsc2缺失的小鼠胚胎成纤维细胞的增殖[J]. 基础医学与临床, 2021, 41(7): 951-956.